AKBA
Price
$1.30
Change
+$0.06 (+4.84%)
Updated
May 2, 6:59 PM EST
4 days until earnings call
PRME
Price
$5.61
Change
+$0.34 (+6.45%)
Updated
May 2, 6:59 PM EST
7 days until earnings call
Ad is loading...

Compare predictions AKBA vs PRME

Header iconAKBA vs PRME Comparison
Open Charts AKBA vs PRMEBanner chart's image
Akebia Therapeutics
Price$1.30
Change+$0.06 (+4.84%)
Volume$1.46M
CapitalizationN/A
Prime Medicine
Price$5.61
Change+$0.34 (+6.45%)
Volume$516.75K
CapitalizationN/A
View a ticker or compare two or three
AKBA vs PRME Comparison Chart

Loading...

AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PRMEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AKBA vs. PRME commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and PRME is a StrongBuy.

COMPARISON
Comparison
May 03, 2024
Stock price -- (AKBA: $1.24 vs. PRME: $5.26)
Brand notoriety: AKBA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 51% vs. PRME: 109%
Market capitalization -- AKBA: $260.74M vs. PRME: $631.35M
AKBA [@Biotechnology] is valued at $260.74M. PRME’s [@Biotechnology] market capitalization is $631.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $578.54B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • AKBA’s TA Score: 4 bullish, 6 bearish.
  • PRME’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PRME is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -9.20% price change this week, while PRME (@Biotechnology) price change was +11.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.13%. For the same industry, the average monthly price growth was -1.93%, and the average quarterly price growth was +1240.72%.

Reported Earning Dates

AKBA is expected to report earnings on Aug 01, 2024.

PRME is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+5.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AKBA with price predictions.
OPEN
A.I.dvisor published
a Summary for PRME with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
PRME($631M) has a higher market cap than AKBA($261M). AKBA YTD gains are higher at: 0.323 vs. PRME (-40.632).
AKBAPRMEAKBA / PRME
Capitalization261M631M41%
EBITDAN/AN/A-
Gain YTD0.323-40.632-1%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
8
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 23 days ago
85%
Bullish Trend 2 days ago
66%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 8 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PRMEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAGRX64.850.09
+0.14%
JHancock Fundamental Large Cap Core A
LGOVX26.250.03
+0.11%
Lord Abbett Growth Opportunities R6
ICSCX28.78N/A
N/A
William Blair Small Cap Value I
BINKX8.31N/A
N/A
BlackRock Infrastructure Sust Opps K
TGDIX14.73-0.12
-0.81%
TCW Relative Value Large Cap I

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with AVIR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-1.27%
AVIR - AKBA
34%
Loosely correlated
+4.05%
VCYT - AKBA
33%
Poorly correlated
+2.86%
PHAT - AKBA
31%
Poorly correlated
+2.55%
CRSP - AKBA
31%
Poorly correlated
+1.51%
PRME - AKBA
31%
Poorly correlated
+6.91%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+6.91%
BEAM - PRME
63%
Loosely correlated
+2.45%
NTLA - PRME
62%
Loosely correlated
+5.14%
RLAY - PRME
55%
Loosely correlated
+2.15%
XNCR - PRME
53%
Loosely correlated
+14.28%
ABCL - PRME
51%
Loosely correlated
N/A
More